

USSN 09/884,319
Graham *et al.*

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1-16. (Canceled)

17. (Currently amended) ~~An~~ An isolated antibody which specifically reacts with an IL-1-R intracellular ligand protein comprising the amino acid sequence of SEQ ID NO:2, ~~SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:7,~~ wherein said antibody specifically reacts with an epitope in SEQ ID NO:2.

Claims 18-26 (Canceled)

27. (Withdrawn) The antibody of claim 17, wherein the IL-1-R intracellular ligand protein consists of the amino acid sequence of SEQ ID NO:4.

28. (Withdrawn) The antibody of claim 17, wherein the IL-1-R intracellular ligand protein consists of the amino acid sequence of SEQ ID NO:6.

29. (Withdrawn) The antibody of claim 17, wherein the IL-1-R intracellular ligand protein consists of the amino acid sequence of SEQ ID NO:7.

USSN 09/884,319

Graham *et al.*

30. (Previously presented) The antibody of claim 17, wherein said antibody is a neutralizing antibody.

31. (Currently amended) The antibody of claim 17, wherein said antibody blocks binding of IL-1-R to an IL-1-R intracellular ligand protein consisting of the amino acid sequence of SEQ ID NO:2, ~~SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:7.~~

32. (Previously presented) The antibody of claim 17, wherein said antibody is a polyclonal antibody.

33. (Previously presented) The antibody of claim 17, wherein said antibody is a monoclonal antibody.

34. (Currently amended) The antibody of claim 17, wherein said antibody is obtained using as an immunogen an IL-1-R intracellular ligand protein with a cysteine residue at the carboxyl terminus, wherein said protein consists of the amino acid sequence of SEQ ID NO:2, ~~SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:7.~~

35. (Previously presented) A pharmaceutical composition comprising the antibody of claim 17 and a pharmaceutically acceptable carrier.

36. (Cancelled)

USSN 09/884,319

Graham *et al.*

37. (Currently amended) A An isolated, neutralizing antibody that binds specifically to an IL-1-R intracellular ligand protein consisting of the amino acid sequence of SEQ ID NO:2, ~~SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:7~~, wherein said neutralizing antibody blocks binding of IL-1-R to said IL-1-R intracellular ligand protein.

38. (Previously presented) A pharmaceutical composition comprising the antibody of claim 37 and a pharmaceutically acceptable carrier.

39. (New) An isolated antibody which specifically reacts with an IL-1-R intracellular ligand protein consisting essentially of the amino acid sequence of SEQ ID NO:2.

40. (New) An isolated antibody which specifically reacts with an IL-1-R intracellular ligand protein consisting of the amino acid sequence of SEQ ID NO:2.

41. (New) An isolated antibody which specifically reacts with a sequence present in SEQ ID NO:2.